
Quarterly report 2023-Q3
added 11-09-2023
Aravive Net Debt 2011-2026 | ARAV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.6 M | -53.1 M | -52 M | -54.9 M | -49.7 M | -75.7 M | -201 M | -182 M | -171 M | -12.7 M | 4.13 M | -400 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.13 M | -201 M | -74.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.65 | 1.12 % | $ 1.01 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.9 | -0.18 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.3 | 1.55 % | $ 3.7 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.37 | 1.72 % | $ 151 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Heron Therapeutics
HRTX
|
-7.17 M | - | - | $ 198 M | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.25 | -1.26 % | $ 74.5 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.61 | 8.78 % | $ 152 M | ||
|
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.4 | -0.71 % | $ 235 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Inventiva S.A.
IVA
|
-95.6 M | $ 5.13 | -0.39 % | $ 138 M | ||
|
Jaguar Health
JAGX
|
116 K | $ 0.28 | -27.77 % | $ 653 K | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 19.16 | -2.39 % | $ 1.03 B | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
-973 M | - | - | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.1 | 0.49 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.42 | 0.69 % | $ 2.98 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.42 | -1.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 241.79 | 4.55 % | $ 4.42 B | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Eli Lilly and Company
LLY
|
33.8 B | - | - | $ 783 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.92 | 0.34 % | $ 4.81 M | ||
|
Esperion Therapeutics
ESPR
|
-165 M | - | - | $ 399 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |